<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073744</url>
  </required_header>
  <id_info>
    <org_study_id>NPRCT001</org_study_id>
    <nct_id>NCT05073744</nct_id>
  </id_info>
  <brief_title>Nalbuphine Versus Morphine for Perioperative Tumor Ablation</brief_title>
  <official_title>Analgesic Efficacy and Safety of Nalbuphine Versus Morphine for Perioperative Tumor Ablation: a Randomized, Control, Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, positive control, multicentre trial is designed to compare the analgesic&#xD;
      efficacy and safety of nalbuphine hydrochloride injection and morphine hydrochloride&#xD;
      injection for perioperative tumor ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sedation and analgesia use in tumor ablation is a necessary part of the procedure. However,&#xD;
      the optimal medicine for sedation and analgesia for tumor ablation remains controversial.&#xD;
      Currently, morphine is a traditional opioid used for pain control and anaesthesia. As no&#xD;
      publications have compared the anaesthetic and analgesic effects between nalbuphine and&#xD;
      morphine during tumor ablation, this trial aims to compare the analgesic efficacy and safety&#xD;
      of nalbuphine and morphine for perioperative tumor ablation. In addition, other endpoints in&#xD;
      term of perioperative analgesia indexes, such as ablation time, daily dose, analgesia&#xD;
      satisfaction, quality of life, and safety, etc. will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic efficiency</measure>
    <time_frame>From the begin to 48 hours after procedure</time_frame>
    <description>No. effective cases / No.Total cases * 100%. The numerical rating scale score at the evaluation time point (at rest) ≤3 is considered as effective analgesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>From the begin to 48 hours after procedure</time_frame>
    <description>Pain assessment using the numerical rating scale (NRS), which is composed of 11 numbers spaced from 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;most intense pain&quot;. Patients chose 1 number to represent their pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia satisfaction</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Scored using visual analogue scale, a 10 cm long scale, marked with 10 markers, both ends of 0 point and 10 points respectively. Participant and medical care personnel mark the corresponding position on a ruler that represents their satisfaction. A score of 0 represents extremely dissatisfied and a score of 10 represents very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ablation</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Duration of the whole procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Days from the time of ablation to Discharge time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of continuous ablation without complaining of pain</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>No. ablation without complaining of pain cases / No.Total cases * 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily dosage</measure>
    <time_frame>From nalbuphine/morphine use to 48 hours after procedure</time_frame>
    <description>Total dose of nalbuphine or morphine / Total days of analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>7 days after procedure</time_frame>
    <description>Assessed by telephone, using the standard of Quality of Life Question-Core by the European O-Rganization for Reasearch and Treatment of Cancer (EORTC QLQ-C30 scale,Version 3.0). The evaluation of quality of life from a multi-dimensional perspective can better reflect the connotation of quality of life, which has been applied to measure QOL of cancer patients in many countries and regions. A total of 30 questions will be replied with different points. Higher score represents lower quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety end point</measure>
    <time_frame>From nalbuphine/morphine use to 48 hours after procedure</time_frame>
    <description>Adverse reactions related with nalbuphine or morphine according to &quot;Common Terminology Criteria for Adverse Events&quot; by &quot;National Cancer Institute&quot; (NCI-CTCAE, version5.0)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Nalbuphine Allergy</condition>
  <condition>Ablation</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Tumor ablation using nalbuphine for pain control and anaesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nalbuphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor ablation using morphine for pain control and anaesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine</intervention_name>
    <description>Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation</description>
    <arm_group_label>Tumor ablation using nalbuphine for pain control and anaesthesia</arm_group_label>
    <other_name>Tumor ablation using nalbuphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine hydrochloride injection is used for perioperative tumor ablation</description>
    <arm_group_label>Tumor ablation using morphine for pain control and anaesthesia</arm_group_label>
    <other_name>Tumor ablation using morphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients requiring tumor ablation;&#xD;
&#xD;
          -  Voluntarily participate and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to contrast agent, test drug or other ingredients;&#xD;
&#xD;
          -  With a history of substance abuse, chronic pain and mental illness;&#xD;
&#xD;
          -  Use of any monamine oxidase inhibitor within 14 days prior to randomization;&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  Cannot tolerate ablation due to other reasons;&#xD;
&#xD;
          -  Cannot express their wishes correctly;&#xD;
&#xD;
          -  Poor compliance, unable to complete the trial;&#xD;
&#xD;
          -  Have participated in other drug trials within 30 days prior to enrollment;&#xD;
&#xD;
          -  Judged by the researcher to be unsuitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao-Jun Teng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda Hospital Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Yan Wang</last_name>
    <phone>86 13851821464</phone>
    <email>xywangseu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hai-Dong Zhu, MD</last_name>
    <phone>86-25-83262224</phone>
    <email>zhuhaidong9509@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Province Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospita</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jingmen NO.2People's Hospital</name>
      <address>
        <city>Jingmen</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yichang Central People's Hospital</name>
      <address>
        <city>Yichang</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lishui Municipal Central Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Laurent G, Bertaux G, Martel A, Fraison M, Fromentin S, Gonzalez S, Pierre FS, Wolf JE. A randomized clinical trial of continuous flow nitrous oxide and nalbuphine infusion for sedation of patients during radiofrequency atrial flutter ablation. Pacing Clin Electrophysiol. 2006 Apr;29(4):351-7.</citation>
    <PMID>16650261</PMID>
  </reference>
  <reference>
    <citation>Sun S, Guo Y, Wang T, Huang S. Analgesic Effect Comparison Between Nalbuphine and Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Section. Front Pharmacol. 2020 Nov 16;11:574493. doi: 10.3389/fphar.2020.574493. eCollection 2020.</citation>
    <PMID>33364949</PMID>
  </reference>
  <reference>
    <citation>Yu P, Zhang J, Wang J. Nalbuphine for spinal anesthesia: A systematic review and meta-analysis. Pain Pract. 2021 Apr 22. doi: 10.1111/papr.13021. [Epub ahead of print] Review.</citation>
    <PMID>33887111</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Gao-jun Teng</investigator_full_name>
    <investigator_title>Chair, Center of IR and vascular surgery, Department of radiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Other researchers can contact the PI for data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

